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Summary
Feedback control of cholesterol synthesis is mediated in part by sterol-induced binding of HMG CoA reductase to Insig
proteins in the endoplasmic reticulum (ER). Binding leads to ubiquitination and proteasomal degradation of reductase, a
rate-controlling enzyme in cholesterol synthesis. Using in vitro and in vivo assays, we show that lanosterol, the first sterol
intermediate in cholesterol synthesis, potently stimulates ubiquitination of reductase, whereas cholesterol has no effect
at 10-fold higher concentrations. Lanosterol is not effective in mediating the other action of Insigs, namely to promote ER
retention of SCAP-SREBP complexes, a reaction that is mediated directly by cholesterol. A pair of methyl groups located
in the C4 position of lanosterol confers this differential response. These data indicate that buildup of cholesterol synthesis
intermediates represses the pathway selectively at reductase and reveal a previously unappreciated link between feed-
back inhibition of reductase and carbon flow through the cholesterol synthetic pathway.Introduction
The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase (HMG CoA reductase) catalyzes the reduction of HMG
CoA to mevalonate (Figure 1), a rate-limiting step in the synthe-
sis of cholesterol and nonsterol isoprenoids (Goldstein and
Brown, 1990). HMG CoA reductase is anchored to membranes
of the endoplasmic reticulum (ER) through its hydrophobic
NH2-terminal domain, which consists of eight membrane-
spanning regions separated by short loops (Roitelman et al.,
1992). The membrane domain of reductase precedes a large,
cytosolic COOH-terminal domain that exerts all of the catalytic
activity of the enzyme (Gil et al., 1985; Liscum et al., 1985). The
levels and activity of reductase are governed by a complex,
multivalent regulatory system mediated by products of mevalo-
nate metabolism (Brown and Goldstein, 1980). Part of this reg-
ulatory system involves sterol-induced ubiquitination of reduc-
tase (Ravid et al., 2000), a reaction that is mediated by the
reductase membrane domain and leads to its ER-associated
degradation (Sever et al., 2003a, 2003b).
As demonstrated by three observations, accelerated degra-
dation of reductase requires at least one of a pair of ER mem-
brane proteins called Insig-1 and Insig-2. First, when reductase
is overexpressed in Chinese hamster ovary (CHO) cells by
transfection, the enzyme is no longer subjected to sterol-
accelerated degradation (Sever et al., 2003b). Overexpression
of Insig-1 or Insig-2 restores regulated degradation of overex-
pressed reductase. Second, through the use of RNA interfer-
ence, the combined knockdown of Insig-1 and Insig-2 abo-
lishes sterol-induced ubiquitination of endogenous reductase,
an obligatory reaction in accelerated degradation of the en-
zyme (Sever et al., 2003a). Third, in mutant cells lacking Insig-1,
sterols fail to stimulate sterol-dependent ubiquitination and de-
gradation of reductase (Sever et al., 2004).
Insigs also mediate sterol regulation of another ER mem-CELL METABOLISM : MARCH 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEbrane protein called SREBP cleavage-activating protein (SCAP)
(Yang et al., 2002). SCAP controls the activity of SREBPs, tran-
scription factors that enhance transcription of all of the genes
required for cholesterol synthesis, as well as the LDL receptor
(Brown and Goldstein, 1999). Excess sterols promote the ER
retention of complexes between SCAP and SREBPs, thus pre-
venting their translocation to the Golgi where the SREBPs are
activated by sequential proteolytic cleavages (DeBose-Boyd et
al., 1999; Nohturfft et al., 2000). As a result of this ER retention,
mRNAs encoding SREBP target genes decline and cholesterol
synthesis is suppressed. Insigs bind to SCAP through a region
of the protein that comprises five of its eight membrane-span-
ning helices (Nohturfft et al., 1998; Yang et al., 2002), and the
amino acid sequence of this region bears significant identities
with the corresponding region of reductase. This region has
become known as the sterol-sensing domain (Brown and
Goldstein, 1999). Point mutations within their sterol-sensing
domains prevent SCAP and reductase from binding to Insigs,
thereby abolishing sterol-mediated ER retention of mutant
SCAP-SREBP complexes and sterol-dependent ubiquitination
and degradation of reductase (Sever et al., 2003a; Yabe et al.,
2002; Yang et al., 2002).
The oxygenated cholesterol derivative, 25-hydroxycholes-
terol (25-HC), has been utilized as a general tool in dissecting
the mechanism for sterol regulation, owing to its ability to po-
tently stimulate binding of both SCAP and reductase to Insigs.
The potency of 25-HC and other oxysterols raises the in-
triguing question as to whether an oxygenated metabolite of
cholesterol or cholesterol itself is the physiologic mediator of
sterol regulation.
In the case of SCAP, support for a direct role of cholesterol
in its regulation has been provided by several observations.
The in vitro addition of cholesterol to isolated membranes in-
duced conformational changes in SCAP that exposed a cryptic
trypsin cleavage site (Brown et al., 2002), and coexpressionVIER INC. DOI 10.1016/j.cmet.2005.01.001 179
A R T I C L EFigure 1. Schematic representation of the choles-
terol biosynthetic pathway in animal cells
Sterols evaluated for HMG CoA reductase-ubiquiti-
nating activity are highlighted in red.of Insigs significantly lowered the concentration of cholesterol
required to induce the response (Adams et al., 2003). Recently,
it has been demonstrated that [3H]cholesterol binds to the
membrane domain of SCAP in detergent solution. The binding
of cholesterol was stereospecific and saturable, indicating that
it modulates SCAP activity through direct interaction (Radhak-
rishnan et al., 2004). Oxysterols neither altered SCAP confor-
mation in vitro nor bound the purified membrane domain of
SCAP, indicating that oxysterols act through an indirect mecha-
nism to block SCAP activity. This conclusion is supported by
recent experiments demonstrating that a photoactivated deriv-180ative of cholesterol, but not that of 25-HC, crosslinked to the
membrane domain of SCAP (Adams et al., 2004).
In striking contrast to the results with SCAP, analysis of re-
ductase ubiquitination in vitro revealed that the reaction was
potently stimulated by oxysterols but not by cholesterol (Song
and DeBose-Boyd, 2004). These results suggest that oxyste-
rols derived from cholesterol, but not cholesterol itself, are
physiologic regulators of reductase degradation. Furthermore,
these findings indicate that selective recognition of sterol li-
gands by SCAP and reductase may contribute to the ability of
Insigs to mediate regulation of both proteins through distinctCELL METABOLISM : MARCH 2005
Lanosterol-induced degradation of HMG CoA reductaseFigure 2. Lanosterol and 24,25-dihydrolanosterol stimulate degradation and
ubiquitination of HMG CoA reductase, but do not inhibit processing of SREBPs,
through an Insig-dependent mechanism
A and B) SV-589 cells were set up for experiments on day 0 at 2 × 105 cells per
100-mm dish in medium A supplemented with 10% FCS. On day 2, the cells
were washed with PBS and refed medium A containing 10% lipoprotein-deficient
serum, 50 M sodium compactin, and 50 M sodium mevalonate. In (B), the
medium also contained 10 M MG-132.
A) After 16 hr at 37°C, the cells were switched to medium A containing 10%
lipoprotein-deficient serum, 50 M compactin, 10 mM mevalonate, and the indi-
cated concentration of 25-hydroxycholesterol, lanosterol, or 24,25-dihydrola-
nosterol. After incubation for 5 hr at 37°C, the cells were harvested and subjected
to cell fractionation. Aliquots of the membrane and nuclear extract fractions (10–
45 g protein/lane) were subjected to SDS-PAGE, transferred to nylon mem-
branes, and immunoblot analysis was carried out with 5 g/ml monoclonal IgG-
A9 (against reductase) or 5 g/ml monoclonal IgG-1D2 (against SREBP-2). The
filters were exposed to film at room temperature for 2–30 s.
B) After incubation for 1 hr at 37°C, the cells were harvested, lysed, and sub-
jected to immunoprecipitation with polyclonal anti-HMG CoA reductase as de-
scribed in Experimental Procedures. Aliquots of the immunoprecipitates were
subjected to SDS-PAGE, transferred to nylon membranes, and immunoblot
analysis was carried out with 5 g/ml IgG-A9 (against reductase) or 0.2 g/ml
monoclonal IgG-P4D1 (against ubiquitin). Filters were exposed to film for 2 s–3
min at room temperature.
C) SV-589 cells were set up for experiment at 5 × 104 cells per 60-mm dish in
medium B with 10% FCS. On days 1 and 3, cells were transfected with 400
pmol/dish of VSV-G siRNA (lanes 1–6) or Insig-1 and Insig-2 siRNA (lanes 7–12)
as described in Experimental Procedures. After the second transfection on day
3, cells were incubated for 16 hr at 37°C in medium A containing 10% lipopro-
tein-deficient serum, 50 M compactin, and 50 M mevalonate. On day 4, the
cells were switched to medium A containing 10% lipoprotein-deficient serum, 50
M compactin in the absence (−) or presence (+) of various combinations of 2.5
M 25-hydroxycholesterol, 2.5 M lanosterol, and 10 mM mevalonate as indi-CELL METABOLISM : MARCH 200524,25-DHL treatment led to a decrease of anti-reductase reac-
cated. After 5 hr, cells were harvested for preparation of whole-cell extracts.
Aliquots of the extracts (63 g) were subjected to SDS-PAGE and immunoblot
analysis was carried out with 5 g/ml IgG-A9 (against reductase). The filter was
exposed to film at room temperature for 15 s.mechanisms. It is noteworthy that the 1,1-bisphosphonate es-
ter SR-12813 differentially replaces sterols to promote reduc-
tase ubiquitination and degradation, but not ER retention of
SCAP (Sever et al., 2004), lending credence to the notion of
selective recognition of sterols by SCAP and reductase.
Previous indirect studies implicated that lanosterol, the first
sterol produced in the synthesis of cholesterol (Figure 1), or
one of its metabolites play a major role in feedback inhibition
of reductase (Chen et al., 1988; Frye et al., 1994; Leonard et
al., 1994; Trzaskos, 1995). These observations prompted us, in
the current paper, to directly evaluate lanosterol as a regulator
of reductase ubiquitination and degradation. When added to
intact cells, lanosterol stimulated ubiquitination and degrada-
tion of reductase in a reaction that required Insigs. The activity
of lanosterol in accelerating reductase ubiquitination and de-
gradation appeared specific inasmuch as it did not suppress
SREBP processing. This is consistent with the inability of la-
nosterol to directly bind to the membrane domain of SCAP
(Radhakrishnan et al., 2004). In vitro, lanosterol promoted re-
ductase ubiquitination as efficiently as oxysterols and its activ-
ity was traced to a pair of C4 methyl groups. Taken together,
the current results demonstrate a direct role for lanosterol as a
selective, physiologic regulator of reductase ubiquitination and
degradation.
Results
The experiment shown in Figure 2A was designed to determine
the effects of lanosterol, and its 24,25-reduced metabolite
24,25-dihydrolanosterol (24,25-DHL) (Figure 1), on the steady-
state levels of reductase and nuclear SREBP-2. SV-589 cells,
a line of transformed human fibroblasts (Yamamoto et al.,
1984), were depleted of sterols by incubation for 16 hr in lipo-
protein-deficient serum containing the reductase inhibitor,
compactin (Brown et al., 1978), and the lowest level of mevalo-
nate (50 M) that assures viability. Subsequent to sterol deple-
tion, the cells were treated for an additional 5 hr with various
concentrations of 25-HC, lanosterol, and 24,25-DHL. In addi-
tion, all of the cells received a high level of mevalonate (10 mM)
to provide nonsterol mevalonate metabolites that augment ste-
rol-accelerated degradation of reductase (Sever et al., 2003a).
Following treatments, the cells were harvested and separated
into membrane and nuclear extract fractions. Aliquots of the frac-
tions were then subjected to SDS-PAGE and immunoblotted with
anti-reductase (Figure 2A, top panel) and anti-SREBP-2 (Figure
2A, bottom panel) monoclonal antibodies. In untreated cells,
we observed bands of immunoreactive protein for reductase
(top panel, lane a) and nuclear SREBP-2 (bottom panel, lane
a). In a dose-dependent fashion, 25-HC accelerated both the
degradation of reductase, as indicated by the disappearance
of the reductase band in membranes isolated from treated cells
(top panel, lanes b–d), and the disappearance of nuclear
SREBP-2 (bottom panel, lanes b–d). Similarly, lanosterol and181
A R T I C L Etivity (top panel, lanes e–j); however, neither sterol blocked the
processing of SREBP-2 (bottom panel, lanes e–j). In addition,
lanosterol and 24,25-DHL also failed to inhibit the processing
of SREBP-1 (unpublished data).
We next evaluated lanosterol and 24,25-DHL for the ability
to promote ubiquitination of reductase, a reaction that is
essential for its accelerated degradation (Sever et al., 2003a)
(Figure 2B). Sterol-depleted SV-589 cells were incubated with
various concentrations of 25-HC, lanosterol, and 24,25-DHL in
the presence of the proteasome inhibitor, MG-132 (to prevent
degradation of ubiquitinated reductase). Following treatments,
the cells were harvested, lysed in detergent-containing buffer,
and the lysates were subjected to immunoprecipitation with
polyclonal antibodies against reductase. The resulting immu-
noprecipitates were then subjected to SDS-PAGE and immu-
noblotted with anti-ubiquitin (top panel) or anti-reductase (bot-
tom panel) monoclonal antibodies. When the cells were treated
with 25-HC, reductase became ubiquitinated in a dose-depen-
dent fashion. This was indicated by the appearance of high
molecular weight smears in anti-ubiquitin immunoblots of the
reductase immunoprecipitates (top panel, lanes b–d). Lanos-
terol and 24,25-DHL stimulated ubiquitination of reductase, al-
though with reduced efficiency (approximately 3- and 10-fold
for 24,25-DHL and lanosterol, respectively) (compare lanes b–d
with e–l). Thus, the reductase-ubiquitinating activity of the
methylated sterols coincides with their ability to diminish
steady-state levels of the enzyme.
We next addressed the requirement of Insig-1 and Insig-2 for
lanosterol-dependent downregulation of endogenous reduc-
tase by reducing their expression through RNA interference. In
the experiment of Figure 2C, SV-589 cells were transfected
with duplexes of small-interfering RNA (siRNA) targeting the
control gene, vesicular stomatitis virus glycoprotein (VSV-G),
which is not expressed in the cells, or the combination of
Insig-1 and Insig-2. Subsequent to sterol depletion, the trans-
fected cells were treated for 5 hr with 25-HC or lanosterol in
the absence or presence of 10 mM mevalonate. In control
transfected cells, the combination of 25-HC and 10 mM meval-
onate led to complete disappearance of reductase (lane 5), and
similar results were obtained with lanosterol plus 10 mM me-
valonate (Figure 2C, lane 6). However, when siRNAs targeting
Insig-1 and Insig-2 were introduced into the cells, the reduc-
tase band persisted regardless of treatment with either sterol
(lanes 7–12). Under these conditions, we observed a 90% and
60% decrease in mRNA for Insig-1 and Insig-2, respectively
(unpublished data). The requirement for nonsterol mevalonate-
derived products in downregulating reductase indicates that
25-HC and lanosterol act to stimulate degradation of the en-
zyme through a common, Insig-dependent mechanism (lanes
1–6). Moreover, unpublished transfection studies revealed that
lanosterol-stimulated degradation of reductase required Insigs
and amino acid residues in reductase necessary for the cova-
lent attachment of ubiquitin and Insig binding (Sever et al.,
2003a).
We recently developed a permeabilized cell system that sup-
ports ubiquitination of reductase stimulated by the in vitro ad-
dition of sterols (Song and DeBose-Boyd, 2004). Thus, we next
sought to determine whether the permeabilized cell system
could also support lanosterol-dependent ubiquitination of re-
ductase (Figure 3A). SV-589 cells were depleted of sterols so
as to provide an abundant supply of nonubiquitinated reduc-182tase. Following sterol depletion, the cells were harvested,
washed, and permeabilized with a low concentration of the
mild detergent digitonin. We previously found that permeabiliz-
ing cells in this manner resulted in the release of a substantial
portion of cytosolic proteins into the supernatant after centrifu-
gation, while membrane proteins such as reductase remained
associated with the pellet fraction (Song and DeBose-Boyd,
2004). Pellets of permeabilized cells were subsequently sub-
jected to in vitro treatments with a mixture of FLAG-tagged
ubiquitin, ubiquitin-aldehyde (to inhibit de-ubiquitinating en-
zymes) (Hershko and Rose, 1987), an ATP-regenerating sys-
tem, and various concentrations of 25-HC, lanosterol, 24,25-
DHL, or cholesterol. The reactions were also supplemented
with rat liver cytosol to facilitate the activation of FLAG-ubiqui-
tin and provide factors necessary for possible modifications
required for the reductase-ubiquitinating activity of lanosterol
and 24,25-DHL. Following incubation at 37°C, pellets of per-
meabilized cells were collected by centrifugation, solubilized in
detergent-containing buffer, and subjected to immunoprecipi-
tation with polyclonal antibodies against reductase. The result-
ing immunoprecipitates were then subjected to SDS-PAGE and
immunoblotted with anti-FLAG (Figure 3A, top panel) or anti-
reductase (Figure 3A, bottom panel). In reactions containing
25-HC, reductase became ubiquitinated in a dose-dependent
fashion (top panel, lanes b–d), and similar results were ob-
tained with lanosterol and 24,25-DHL (top panel, lanes e–g and
h–j, respectively). Cholesterol only modestly stimulated the re-
action and was at least 10-fold less potent than lanosterol and
24,25-DHL (top panel, lanes k and l). Importantly, it should be
noted that while lanosterol and 24,25-DHL were found to be
3- to 10-fold less potent than 25-HC in stimulating reductase
ubiquitination in intact cells (see Figure 2), in permeabilized
cells, the activities of both methylated sterols were equivalent
to or greater than that of 25-HC.
We next determined whether other intermediates of choles-
terol synthesis could promote ubiquitination of reductase in
permeabilized cells. Of particular interest were zymosterol and
zymostenol, which are demethylation products of lanosterol
and 24,25-DHL, respectively (Figure 1). As shown in Figure 3B,
lanosterol and 24,25-DHL were the only cholesterol synthesis
intermediates that stimulated reductase ubiquitination to ap-
preciable levels (top panel, lanes 5 and 6). In addition, zymos-
terol, zymostenol, desmosterol, and 7-dehydrocholesterol nei-
ther promoted reductase ubiquitination and degradation nor
inhibited SREBP processing in intact cells (unpublished data).
Thus, the failure of zymosterol and zymostenol to influence re-
ductase ubiquitination in permeabilized cells establishes the
importance of C4 and/or C14 methylation in the recognition of
lanosterol and 24,25-DHL by the regulatory system that medi-
ates ubiquitination and degradation of reductase.
Previously, we found that a specific set of oxysterols stim-
ulated reductase ubiquitination when added in vitro at concen-
trations less than 25 M (Song and DeBose-Boyd, 2004). The
experiment of Figure 4B shows an extended analysis of the
sterol specificity for reductase ubiquitination in permeabilized
cells (see Figure 4A). Of the sterols tested, only 25-HC, lanos-
terol, 27-hydroxylanosterol, 7-keto-25-hydroxycholesterol, and
27-hydroxycholesterol stimulated reductase ubiquitination to
appreciable levels (Figure 4B, top panels, lanes A, B, C, E, and
H). In particular, 27-hydroxylanosterol strongly stimulated re-
ductase ubiquitination, prompting us to compare its ubiquiti-CELL METABOLISM : MARCH 2005
Lanosterol-induced degradation of HMG CoA reductaseFigure 3. Lanosterol and 24,25-dihydrolanosterol promote ubiquitination of HMG
CoA reductase in permeabilized cells
SV-589 cells were set up and refed as described in the legend to Figure 2. On
day 3, the cells were harvested and permeabilized with digitonin as described in
Experimental Procedures. The permeabilized cells were resuspended in permea-
bilization buffer containing protease inhibitors, an ATP-regenerating system, 0.1
mg/ml FLAG-ubiquitin, 0.01 mg/ml ubiquitin-aldehyde, and 3 mg/ml rat liver cy-
tosol.
A) Reactions containing the indicated concentration of 25-hydroxycholesterol
(lanes b–d), lanosterol (lanes e–g), 24,25-dihydrolanosterol (lanes h–j), or choles-
terol (lanes k–l) were incubated for 30 min at 37°C, after which they were termi-
nated by centrifugation for 10 min at 4°C. The resulting cell pellets were lysed
and subjected to immunoprecipitation with polyclonal anti-HMG CoA reductase
as described in Experimental Procedures. Aliquots of the immunoprecipitates
were subjected to SDS-PAGE, transferred to nylon membranes, and immu-
noblotted with 5 g/ml IgG-A9 (against reductase) or 1 g/ml monoclonal IgG-
M2 (against FLAG-ubiquitin). Filters were exposed to film at room temperature
for 30 s.
B) Reactions containing 25 M of the indicated sterol were carried out for 30
min at 37°C, after which they were terminated by centrifugation. The resulting
cell pellets were lysed and subjected to immunoprecipitation and immunoblot
analysis as in (A). Filters were exposed to film at room temperature for 1–30 s.nating activity at lower concentrations to that of other positive
sterols at 25 M. As shown in Figure 4C, 2.5 M 27-hydrox-
ylanosterol stimulated approximately equivalent levels of re-
ductase ubiquitination as 25 M lanosterol (top panel, com-CELL METABOLISM : MARCH 2005pare lanes 3 and 7). Together, these results indicate that
hydroxyl groups in the sterol side chain and methyl groups at
the C4 and/or C14 position are key determinants for recogni-
tion in the sterol-sensing phase of reductase degradation.
We next designed experiments to determine the relative con-
tribution of the methyl groups in lanosterol for stimulating re-
ductase ubiquitination and degradation. For this purpose, we
compared the activities of several sterols with or without C4
methyl substitutions to those of lanosterol and 24,25-DHL (Fig-
ure 5A). In intact cells, the 4,4-dimethylated analog of choles-
terol (4,4-dimethylcholesterol) stimulated reductase ubiquitina-
tion (Figure 5B, top panel, lane E) and degradation (Figure 5C,
lane E) with an activity approximately equivalent to that of la-
nosterol and 24,25-DHL (Figures 5B and 5C, lanes B and C).
Reduced levels of reductase ubiquitination and degradation
were observed with C4 dimethylated cholestenone (Figures 5B
and 5C, lane I), suggesting that optimal activity requires a hy-
droxyl group at the 3β position in addition to the 4,4-dimethyl
moiety. Lophenol, which contains a single methyl group in the
C4 position, modestly promoted the ubiquitination and degra-
dation of reductase (Figures 5B and 5C, lane G), highlighting
the importance of the two C4 methyl groups. Importantly, 4,4-
dimethylcholesterol, 4,4-dimethylcholestenone, and lophenol
did not inhibit processing of SREBP-2 (Figure 5D, lanes E, G,
and I).
We next evaluated the methylated sterols for their ability to
stimulate reductase ubiquitination in vitro. Ubiquitination reac-
tions of isolated membrane fractions were supplemented with
purified ubiquitin-activating enzyme (E1), rather than rat liver
cytosol, as a source of ubiquitin-activating activity (Song and
DeBose-Boyd, 2004). As depicted in Figure 5E, 4,4-dimeth-
ylcholesterol was a potent agonist of E1-mediated reductase
ubiquitination with an efficiency similar to 25-HC, lanosterol,
and 24,25-DHL (top panel, compare lane E with lanes A–C). As
we observed in intact cells, the activities of lophenol and 4,4-
dimethylcholestenone in promoting the ubiquitination of reduc-
tase were reduced in comparison to 4,4-dimethylcholesterol
(top panel, lanes G and I, respectively).
Finally, we sought to determine whether protein phosphory-
lation plays a role in regulated ubiquitination of reductase. In
the experiment of Figure 6, ATP and its nonhydrolyzable ana-
log, adenylyl-imidodiphosphate (AMP-PNP), were utilized as
energy sources in ubiquitination reactions conducted with iso-
lated membranes. In the absence of an energy source, no
ubiquitinated reductase was observed upon the addition of 25-
HC, lanosterol, or 24,25-DHL to reaction mixtures (top panel,
lanes 1–4). Regulated ubiquitination of reductase was restored
when the reactions were supplemented with ATP (top panel,
lanes 5–8) or AMP-PNP (top panel, lanes 9–12). Given that
AMP-PNP allows ubiquitin activation by E1 (Johnston and Co-
hen, 1991; Pickart et al., 1994) but cannot function as a protein
kinase substrate, these results indicate that neither 25-HC nor
methylated sterols require protein phosphorylation in order to
stimulate ubiquitination of reductase in vitro.
Discussion
The current results provide evidence for a major role of the
cholesterol synthesis intermediate lanosterol in posttranscrip-
tional regulation of HMG CoA reductase. When delivered to
intact SV-589 cells, lanosterol triggered rapid degradation and183
A R T I C L EFigure 4. Sterol specificity for HMG CoA reductase
ubiquitination in permeabilized cells
A) Structures of the sterols evaluated for stimulating
ubiquitination of HMG CoA reductase in (B) and (C).
B and C) SV-589 cells were set up and refed as
described in the legend to Figure 2. On day 3, the
cells were harvested and permeabilized with digi-
tonin as described in Experimental Procedures. The
permeabilized cells were resuspended in permeabil-
ization buffer containing protease inhibitors, an ATP-
regenerating system, 0.1 mg/ml FLAG-ubiquitin,
0.01 mg/ml ubiquitin-aldehyde, and 3 mg/ml rat liver
cytosol. Incubations were carried out for 30 min in
the presence of 25 M of the indicated sterol in (B).
In (C), reactions contained 25 M 25-hydroxycho-
lesterol, lanosterol, 27-hydroxycholesterol, and 24,25-
dihydrolanosterol or 0.75, 2.5, 7.5, and 25 M 27-
hydroxylanosterol as indicated. After 30 min at
37°C, the reactions were terminated by centrifuga-
tion. The resulting cell pellets were lysed and sub-
jected to immunoprecipitation and immunoblot analy-
sis as described in the legend to Figure 3. Filters were
exposed to film at room temperature for 2–20 s.ubiquitination of reductase (Figures 2A and 2B). The character-
istics of lanosterol-mediated regulation of reductase mimicked
those of 25-HC with the following respects: (1) nonsterol end
products of mevalonate metabolism augmented both lanos-
terol- and 25-HC-dependent degradation of reductase (Figure
2C, lanes 1–6) and (2) the combined knockdown of Insig-1 and
Insig-2 abolished 25-HC and lanosterol-mediated degradation
of reductase (Figure 2C, lanes 7–12). Despite its potent activity
in promoting reductase degradation, lanosterol was not effec-
tive in suppressing SREBP processing in intact cells as did 25-
HC (Figure 2). The possibility remains that in permeabilized
cells, lanosterol could influence the activity of SCAP with much
lower potency than that for reductase. Unfortunately, the per-
meabilized cell system is not amenable to the study of SREBP
processing or sterol-mediated retention of SCAP-SREBP. How-184ever, the failure of lanosterol to modulate SREBP processing in
intact cells is consistent with its inability to directly bind the
SCAP membrane domain (Radhakrishnan et al., 2004) and
modulate SCAP conformation in vitro (Brown et al., 2002).
The potency of lanosterol-induced ubiquitination of reduc-
tase was 3- to 10-fold less than that of 25-HC in intact cells
(Figure 2B). We reasoned that in aqueous culture medium, the
reduced solubility of the methylated sterols in comparison to
25-HC limits their access to membranes of intracellular organ-
elles. In light of this, lanosterol and 24,25-DHL should achieve
a higher effective concentration when delivered directly to ER
membranes in vitro and thus exhibit an enhanced potency. We
found this to be the case as the methylated sterols stimulated
reductase ubiquitination as potently as 25-HC when added to
permeabilized cells and isolated membranes (Figures 3 and 5).CELL METABOLISM : MARCH 2005
Lanosterol-induced degradation of HMG CoA reductaseFigure 5. 4,4-dimethyl moiety of lanosterol is suffi-
cient to promote ubiquitination and degradation of
HMG CoA reductase
A) Structures of the sterols evaluated for stimulating
ubiquitination of HMG CoA reductase in (B)–(E). SV-
589 cells were set up and refed as described in the
legend to Figure 2.
B–D) On day 3, the cells were switched to medium
A containing 10% lipoprotein-deficient serum, 50
M compactin, either 10 M MG-132 (B) or 10 mM
mevalonate (C and D), and 2.5 M of the indicated
sterol. (B) Following incubation at 37°C for 1 hr, the
cells were harvested, lysed, and subjected sequen-
tially to immunoprecipitation, SDS-PAGE, and im-
munoblot analysis as described in the legend to Fig-
ure 2. Filters were exposed to film for 1 s. (C and D)
Following incubation at 37°C for 5 hr, the cells were
harvested and sequentially subjected to cell frac-
tionation. Aliquots of the membrane fractions (C, 10
g protein/lane) and nuclear extracts (D, 35 g pro-
tein/lane) were subjected to SDS-PAGE and immu-
noblot analysis as described in the legend to Figure
2. Filters were exposed to film at room temperature
for 1 s–2 min.
E) On day 3, the cells were harvested, washed, and
subjected to cell fractionation as described in Experi-
mental Procedures. Aliquots of isolated membrane
fractions were resuspended in permeabilization buffer
containing protease inhibitors, the ATP-regenerating
system, 0.1 mg/ml FLAG-ubiquitin, 0.01 mg/ml ubiqu-
itin aldehyde, and 5 g/ml purified ubiquitin-activating
enzyme. Incubations were carried out at 37°C in the
absence (−) or presence (+) of 25 M of the indicated
sterol. After 30 min, the reactions were terminated by
centrifugation, and the resulting cell pellets were
subjected to immunoprecipitation and immunoblot
analysis as described in the legend to Figure 4. Fil-
ters were exposed to film at room temperature for
15 s–5 min.The 4,4-dimethyl moiety of lanosterol appears to be the ma-
jor determinant for reductase regulation as indicated by the
ability of 4,4-dimethylcholesterol, but not cholesterol, to pro-
mote reductase ubiquitination in intact cells and in vitro (Figure
5). On the other hand, the 3β-hydroxyl group seems to play a
secondary role in recognition of lanosterol since 4,4-dimeth-
ylcholestenone, which contains a 3-keto group in place of the
3β-hydroxyl group, exhibited reduced reductase-ubiquitinating
activity in comparison to 4,4-dimethylcholesterol. The impor-
tance of 4,4-dimethylation is somewhat surprising considering
that a comparative analysis of the molecular structures of cho-
lesterol and lanosterol reveals that lanosterol is structurally flat-
ter than cholesterol in its hydrophobic region (Miao et al.,
2002). In both sterols, this region consists of a planar steroid
ring and a short hydrocarbon tail, and in particular, the C14
methyl group of lanosterol protrudes from the steroid ring.
While evidence for the participation of C14 methylation is lack-
ing, the ability of 4,4-dimethylcholesterol to stimulate reduc-
tase ubiquitination indicates that the C14 methyl group plays a
minor role in the process.
Stimulation of reductase ubiquitination by lanosterol could
be mediated solely by ubiquitin-activating enzyme (E1) (Figure
5D). Thus, lanosterol does not require modifications by cyto-
solic enzymes in order to stimulate in vitro ubiquitination of
reductase, indicating that lanosterol is directly recognized inCELL METABOLISM : MARCH 2005the sterol-sensing reaction. This is an important conclusion in
view of previous studies demonstrating that oxylanosterols, en-
dogenous oxysterols generated during the demethylation of la-
nosterol, can also accelerate reductase degradation (Frye et
al., 1994; Trzaskos, 1995). Inasmuch as oxylanosterols are tran-
sient intermediates in lanosterol demethylation, they would not
be expected to accumulate within cells, suggesting that their
role in the feedback control of reductase would be minor at
best. Moreover, in vitro, E1-mediated ubiquitination of reduc-
tase was stimulated by lanosterol in reactions that were not
supplemented with NADPH, an essential cofactor required for
the generation of oxylanosterols (Gaylor, 2002).
The lack of cytosol requirement also indicates that lanosterol
does not require presentation to membranes by cytosolic pro-
teins in order to promote reductase ubiquitination, supporting
our previous notion that the sterol-sensing mechanism occurs
at the membrane (Song and DeBose-Boyd, 2004). Interestingly,
the sterol 27-hydroxylanosterol was found to be the most po-
tent of all sterols tested for reductase ubiquitination. The meth-
ylation and side chain hydroxylation of 27-hydroxylanosterol
appear to act synergistically in promoting reductase ubiquitina-
tion, indicating that side chain hydroxylation is a third structural
feature recognized by the reductase sterol-sensing machinery.
It should be noted that while C4-dimethylated sterols are spe-
cific for reductase, side chain hydroxylated sterols regulate185
A R T I C L EFigure 6. Protein phosphorylation is not a requirement for sterol-dependent
ubiquitination of HMG CoA reductase in vitro
On day 0, SV-589 cells were set up and refed as described in the legend to
Figure 2. On day 3, the cells were harvested, washed, and subjected to cell
fractionation as described in Experimental Procedures. Aliquots of isolated mem-
brane fractions were resuspended in permeabilization buffer containing protease
inhibitors, 0.1 mg/ml FLAG-ubiquitin, 0.01 mg/ml ubiquitin aldehyde, 5 g/ml
purified ubiquitin-activating enzyme, and 1 mM ATP or AMP-PNP substituted for
the ATP-regenerating system. Incubations were carried out at 37°C in the ab-
sence (−) or presence (+) of 25 M of the indicated sterol. After 30 min, the
reactions were terminated by centrifugation, and the resulting cell pellets were
subjected to immunoprecipitation and immunoblot analysis as described in the
legend to Figure 3. Filters were exposed to film at room temperature for 3–15 s.both reductase and SCAP. It is presently unclear whether ste-
rol-sensing involves direct binding of methylsterols and oxy-
sterols to reductase itself or to another membrane bound protein
that in turn acts on the reductase. Furthermore, it is unclear as to
whether oxysterols and methylated sterols are recognized
through the same mechanism in the sensing reaction. Interest-
ingly, 25-HC and cholesterol appear to modulate SCAP
through distinct mechanisms: oxysterols act indirectly through
another protein, whereas cholesterol acts by directly binding to
SCAP (Adams et al., 2004). Perhaps 25-HC and other oxyste-
rols act on reductase and SCAP through a shared mechanism
while cholesterol and lanosterol act by direct binding to the
membrane domains of SCAP and reductase, respectively. Ef-
forts are currently being undertaken to resolve these issues
and characterize the reductase sterol-sensing reaction in
more detail.
The importance of reductase to the maintenance of choles-
terol homeostasis is highlighted by its tight control through a
complex, multivalent regulatory system (Brown and Goldstein,
1980; Goldstein and Brown, 1990). Sterol and nonsterol by-
products of the cholesterol biosynthetic pathway reduce activ-
ity of reductase by inhibiting transcription of the reductase
gene, blocking translation of reductase mRNA, and accelerat-
ing degradation of the reductase protein. While the mechanism
for the translational regulation of reductase is unknown, the
current results provide a clearer understanding of how cells
coordinate transcriptional control of reductase, which is mediated
by SCAP-SREBP, with the regulation of reductase stability.
Figure 7 shows a model for Insig-dependent regulation of
reductase mediated by three types of sterols: oxysterols, cho-186Figure 7. Model for sterol-mediated regulation of HMG CoA reductase
As discussed in the text, HMG CoA reductase is subject to feedback inhibition
by cholesterol, oxysterols, and methylated sterols such as lanosterol. Cholesterol
derived either from endogenous synthesis or via LDL receptors inhibits reductase
activity by suppressing the activation of SREBPs through SCAP. Oxysterols de-
rived from the conversion of endogenous and/or exogenous cholesterol inhibit
reductase by accelerating its degradation and by suppressing the activation of
SREBPs. Lanosterol, through its C4-dimethylation, downregulates reductase
solely by accelerating degradation of the enzyme. Through these reactions, cho-
lesterol synthesis is maintained such that important by-products of the synthetic
pathway are continually provided, while at the same time avoiding the toxic over-
accumulation of cholesterol.lesterol, and methylated sterols such as lanosterol. Oxysterols
derived either by the conversion of endogenous or LDL-derived
cholesterol downregulate reductase through two mechanisms:
accelerated degradation of the reductase protein and inhibition
of reductase gene transcription by blocking the ER to Golgi
transport of SCAP-SREBP. Cholesterol does not influence re-
ductase stability directly but acts indirectly to downregulate
reductase by blocking the activity of SCAP-SREBP. On the
other hand, lanosterol selectively accelerates the degradation
of reductase without effect on ER to Golgi transport of SCAP-
SREBP.
The aforementioned findings are significant in the following
respects. First, the selective recognition of cholesterol and la-
nosterol by SCAP and reductase, respectively, helps to explain
how Insigs mediate regulation of both proteins through distinct
mechanisms. Second, the current results point to the synthesis
of lanosterol, the first sterol produced in the cholesterol syn-
thetic pathway, as a key focal point in sterol regulation. Lanos-
terol demethylation has been implicated as a rate-limiting stepCELL METABOLISM : MARCH 2005
Lanosterol-induced degradation of HMG CoA reductasein cholesterol synthesis (Spence and Gaylor, 1977; Williams et
al., 1977), and it seems reasonable for lanosterol to inhibit its
own synthesis through the downregulation of reductase, thus
reducing flux through the sterol pathway. It should be noted
that a nonsterol mevalonate metabolite, most likely derived
from geranylgeranyl pyrophosphate (Sever et al., 2003a), en-
hances sterol-accelerated degradation of reductase. Thus, an
intricate link between reductase stability and carbon flux
through the cholesterol biosynthetic pathway is attainted, and
we envision this process to be the first in a series of reactions
that guard against sterol overaccumulation. The accumulation
of lanosterol is prevented, owing to its inability to mediate sup-
pression of SREBP processing through SCAP. Under such con-
ditions, mRNAs encoding enzymes that catalyze reactions sub-
sequent to lanosterol synthesis remain elevated, allowing
metabolism of lanosterol to cholesterol. The necessity of this
conversion is highlighted by the ability of cholesterol, rather
than lanosterol, to optimize certain physical properties of cell
membranes with regard to biological functions (Miao et al.,
2002; Smondyrev and Berkowitz, 2001). Finally, the specificity
of lanosterol for reductase may permit the identification of pro-
teins selectively recruited to the reductase-Insig complex.
The novel behavior of lanosterol and 24,25-DHL in uncou-
pling regulation of reductase from the regulation of SCAP-
SREBP is important from clinical as well as the aforementioned
biological perspectives. Statins, a group of competitive inhibi-
tors of reductase, reduce the incidence of heart attacks and
prolong the lives of subjects with pre-existing coronary artery
disease (Heart Protection Study Collaborative Group, 2002;
Scandinavian Simvastatin Study Group, 1994). However, this
inhibition reduces mevalonate-derived products that govern re-
ductase activity through the multivalent feedback mechanism.
The absence of such regulatory molecules contributes to a ma-
jor increase in the amount of active reductase in statin-treated
animals (and presumably humans) that becomes progressively
harder to inhibit (Kita et al., 1980; Singer et al., 1984). In theory,
this compensatory increase of reductase should be reduced by
an agent that accelerates the degradation of the accumulated
enzyme. Thus, understanding how C4-dimethylation of lanos-
terol specifically triggers reductase degradation, but not ER
retention of SCAP-SREBP (which ultimately governs LDL re-
ceptor expression), may lead to the development of novel hy-
pocholesterolemic agents. Considering the recent recommen-
dation for more aggressive cholesterol-lowering strategies
(Grundy et al., 2004), these new agents may be utilized to po-
tentiate the therapeutic effectiveness of statins.
Experimental procedures
Materials
We obtained MG-132 and digitonin from Calbiochem; horseradish peroxi-
dase-conjugated donkey anti-mouse and anti-rabbit IgG (affinity purified)
from Jackson ImmunoResearch Laboratories; ubiquitin, ubiquitin-aldehyde,
and ubiquitin-activating enzyme from Boston Biochem (Cambridge, Mas-
sachusetts); sterols (see Figures 1, 4, and 5) from Steraloids, Inc. (Newport,
Rhode Island), Research Plus, Inc. (South Plainfield, New Jersey), and
Sigma; and NH2-terminal FLAG-tagged ubiquitin from Sigma. Other re-
agents were obtained from described sources (DeBose-Boyd et al., 1999).
Lipoprotein-deficient serum (d > 1.215 g/ml) was prepared from newborn
calf serum by ultracentrifugation (Goldstein et al., 1983).
27-hydroxylanosterol (25R,26-hydroxylanosterol) was synthesized fromCELL METABOLISM : MARCH 2005lanosterol (Sigma-Aldrich, St. Louis, Missouri) by selective selenium dioxide
oxidation using minor modifications of previous procedures (Camps et al.,
1978). The final product has a mass spectrum identical to that of the natu-
rally occurring diol (Pikuleva and Javitt, 2003), and NMR analysis (Byron
Arison) confirmed the stereospecificity of the 25R,26-hydroxylation.
Cell culture
Monolayers of SV-589 cells, an immortalized line of human fibroblasts ex-
pressing the SV40 large T antigen (Yamamoto et al., 1984), were maintained
in tissue culture at 37°C in 5% CO2. Stock cultures of SV-589 cells were
grown in medium A (Dulbecco’s modified Eagle’s medium containing 100
units/ml penicillin and 100 g/ml streptomycin sulfate) supplemented with
10% (v/v) fetal calf serum (FCS).
Cell fractionation and immunoblot analysis
Pooled cell pellets were used to isolate nuclear extracts, 2 × 105 g mem-
brane fractions, or whole-cell lysate fractions, and subjected to 8% SDS-
PAGE and immunoblot analysis as previously described (Sever et al.,
2003b). Primary antibodies used for immunoblotting were as follows: mouse
monoclonal anti-T7-Tag (IgG2b) (Novagen); mouse monoclonal anti-Myc
(IgG fraction) from the culture medium of hybridoma clone 9E10 (American
Type Culture Collection); IgG-A9, a mouse monoclonal antibody against the
catalytic domain of hamster HMG CoA reductase (amino acids 450–887)
(Liscum et al., 1983); IgG-1D2, a mouse monoclonal antibody against the
NH2 terminus of human SREBP-2 (amino acids 48–403) (Yabe et al., 2002);
IgG-P4D1, a mouse monoclonal antibody against bovine ubiquitin (Santa
Cruz Biotechnology); and IgG-M2, a mouse monoclonal antibody against
the FLAG epitope (Sigma).
Ubiquitination of HMG CoA reductase in intact cells
The conditions of incubations prior to harvesting of cells are described in
the figure legends. At the end of the incubations, the cells were harvested,
lysed in detergent-containing buffer, and immunoprecipitations were carried
out with polyclonal antibodies directed against the 60 kDa COOH-terminal
domain of human HMG CoA reductase as previously described (Sato et al.,
1993; Sever et al., 2003a). Aliquots of the immunoprecipitates were sub-
jected to 6% SDS-PAGE, transferred to nylon membranes, and subjected
to immunoblot analysis.
Ubiquitination of HMG CoA reductase in permeabilized
cells and isolated membranes
The conditions of incubations prior to harvesting of cells are described in
the figure legends. SV-589 cells were harvested into the medium by scrap-
ing and collected by centrifugation, after which pooled cell pellets from
triplicate dishes were washed with phosphate-buffered saline and either
permeabilized with 0.025% (w/v) digitonin or subjected to cell fractionation
for the isolation of membrane fractions as described above. Permeabilized
cells and membranes were resuspended in 300 l and 150 l, respectively,
of permeabilization buffer (25 mM Hepes-KOH at pH 7.3, 115 mM potas-
sium acetate, 5 mM sodium acetate, 2.5 mM magnesium chloride, 0.5 mM
sodium EGTA) containing protease inhibitors (20 M leupeptin, 10 M MG-
132, 5 g/ml pepstatin A, and 2 g/ml aprotinin), an ATP-regenerating sys-
tem (2 mM Hepes-KOH at pH 7.3, 1 mM magnesium acetate, 1 mM sodium
ATP, 30 mM creatine phosphate, and 0.05 mg/ml creatine kinase), 0.1 mg/ml
FLAG-ubiquitin, and 0.01 mg/ml ubiquitin-aldehyde. The source of ubiqui-
tin-activating activity was provided by the addition of either 3 mg/ml rat
liver cytosol (Song and DeBose-Boyd, 2004) or 5 g/ml purified ubiquitin-
activating enzyme (E1). Sterols were added to reactions in a final concentra-
tion of 1% (v/v) ethanol. Typical reactions were carried out at 37°C for 30
min, unless otherwise stated in the figure legends. Reactions were termi-
nated by centrifugation at 4,000 rpm (permeabilized cells) or 2 × 105 g
(isolated membranes) at 4°C, and the resulting pellets were lysed in de-
tergent-containing buffer, clarified, and subjected to immunoprecipitation
with polyclonal anti-HMG CoA reductase as described above.
RNA interference
Duplexes of small-interfering RNA targeting Insig-1, Insig-2, and the irrele-
vant control gene VSV-G were synthesized by Dharmacon Research (Lafayette,187
A R T I C L EColorado), and RNA interference experiments were carried out as previously
described (Sever et al., 2003a).
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